Presentation is loading. Please wait.

Presentation is loading. Please wait.

Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking.

Published byLoreen Riley Modified over 6 years ago

Similar presentations

Presentation on theme: "Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking."— Presentation transcript:

1 Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation
From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination “ Baby Pills” in Zambia: A Randomized Controlled Trial Clin Infect Dis. 2010;51(9): doi: /656628 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

2 Table 1. Baseline Characteristics and Follow-up
From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination “ Baby Pills” in Zambia: A Randomized Controlled Trial Clin Infect Dis. 2010;51(9): doi: /656628 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

3 Figure 1. CONSORT (Consolidated Standards of Reporting Trials) flow diagram. The asterisk (*) indicates that the child was mistakenly considered to not meet World Health Organization criteria for antiretroviral therapy (ART) and was not prescribed drugs or followed up. From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination “ Baby Pills” in Zambia: A Randomized Controlled Trial Clin Infect Dis. 2010;51(9): doi: /656628 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

4 Figure 2. Time to first primary (A) and secondary (B) adverse event (AE) outcomes. Primary AEs were grade 3 or 4 AEs with a definite/probable or uncertain relationship with nevirapine; secondary AEs were grade 2–4 AEs with a definite/probable relationship with nevirapine. From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination “ Baby Pills” in Zambia: A Randomized Controlled Trial Clin Infect Dis. 2010;51(9): doi: /656628 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

5 Table 2. Adverse Events (AEs)
From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking Pediatric Fixed-Dose Combination “ Baby Pills” in Zambia: A Randomized Controlled Trial Clin Infect Dis. 2010;51(9): doi: /656628 Clin Infect Dis | © 2010 by the Infectious Diseases Society of America

Download ppt "Table 3. Predictors of Nevirapine Reactions at Antiretroviral Therapy Initiation From: Strategies for Nevirapine Initiation in HIV-Infected Children Taking."

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.
Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:1338- 1347.

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:
TREATMENT OF SEVERE PNEUMONIA WITH ORAL ANTIBIOTICS Lozano JM, on behalf of the APPIS Trial Group. Department of Pediatrics and Clinical Epidemiology Unit,

TREATMENT OF SEVERE PNEUMONIA WITH ORAL ANTIBIOTICS Lozano JM, on behalf of the APPIS Trial Group. Department of Pediatrics and Clinical Epidemiology Unit,
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:

American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:
Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.

Long-Term Comparison of Nevirapine Versus Efavirenz When Combined with Other Antiretroviral Drugs in HIV-1 Positive Antiretroviral-Naïve Persons- The NNRTI.
Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.

Date of download: 9/17/2016 From: Behavioral Therapy to Enable Women with Urge Incontinence to Discontinue Drug Treatment: A Randomized Trial Ann Intern.
Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4

Glecaprevir-Pibrentasvir in GT 1-6 with Renal Disease EXPEDITION-4
Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.
Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.

Figure 2 Power of likelihood ratio, log-rank, and Fisher’s exact tests as a function of the relative risk (RR) for different proportions of susceptible.
Figure 1 Overview of Markov model for infected total hip arthroplasty

Figure 1 Overview of Markov model for infected total hip arthroplasty
Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced
Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.

Table 4 Risk factors for acquisition of vancomycin-resistant enterococcal (VRE) colonization after transplantation for 120 liver transplant recipients.
Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.

Table 5 Characteristics of 12 patients who had 1 test of stool samples that yielded positive results in the prospective clinical assessment for investigation.
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.

Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.

Figure 1. Varicella-related outpatient visit rates by age group, MarketScan 2003–2012. Varicella was the primary diagnosis code for data shown. Annual.
Fig. 1. Time line for investigations

Fig. 1. Time line for investigations
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital 

Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital 
Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.

Table 6 The results of virus isolation tests before and after oseltamivir therapy. From: A Comparison of the Effectiveness of Oseltamivir for the Treatment.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

Similar presentations

Ads by Google